Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Xarelto AG Logs 9.6 Billion Yen on NHI Basis in April-September: Qol
Qol Holdings said on November 7 that sales of the authorized generic (AG) version of anticoagulant Xarelto (rivaroxaban), launched in December 2024 by its subsidiary Daiichi Sankyo Espha, totaled 9.64 billion yen on an NHI price basis in April-September 2025.…
To read the full story
Related Article
- Nichi-Iko’s Xarelto Generic Adds VTE Use
February 2, 2026
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
- Xarelto Generics Win Adult, Pediatric VTE Indication Expansions
December 18, 2025
- Espha/Bayer Unit Add Pediatric Indication to Xarelto AG
December 11, 2025
- First Generics of Equa Priced at 30% of Original Product
December 6, 2024
- Xarelto, Equa Face Generic Debuts in Japan: December Listing
December 5, 2024
- Bayer Set to Finally List Xarelto AG in December, Espha as Distributor
August 20, 2024
BUSINESS
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
- New JCR President Confident in 100 Billion Yen Sales Target in 2030s
April 3, 2026
- Meiji Launches Rezurock in Thailand
April 3, 2026
- Mochida, LG Chem Ink Licensing Deal for Dienogest in South Korea, Thailand
April 3, 2026
- Lotte Invests in Rakuten Medical via Biopharma CVC
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…